Table 4.
Breakthrough Invasive Fungal Infections During Isavuconazole, Posaconazole, and Voriconazole Primary Prophylaxis in Patients Undergoing Treatment for Acute Myeloid Leukemia
| Characteristic | ISA | POS | P Value | VOR | P Valuea |
|---|---|---|---|---|---|
| Indication | |||||
| De novo AML induction chemotherapy | |||||
| bIFI, No. | 3 | 1 | 0 | ||
| Organism, No. | |||||
| Aspergillus fumigatus | 1b | 0 | 0 | ||
| Aspergillus spp | 2 | 0 | 0 | ||
| Candida glabrata | 0 | 1 | 0 | ||
| Courses, No. | 38 | 37 | 72 | ||
| bIFI, % of courses | 7.9 | 2.7 | .6 | 0 | .04 |
| R/R AML salvage/reinduction chemotherapy | |||||
| bIFI, No. | 6 | 2 | 1 | ||
| Organism, No. | |||||
| Aspergillus fumigatus | 3 | 1 | 0 | ||
| Rhizopus microsporus/azygosporus | 1 | 0 | 0 | ||
| Fusarium spp | 2 | 1 | 0 | ||
| Scedosporium apiospermum | 0 | 0 | 1 | ||
| Courses, No. | 50 | 36 | 18 | ||
| bIFI, % of courses | 12 | 5.5 | .4 | 5.5 | .7 |
| Total courses, No. | 88 | 73 | 90 | ||
| Total bIFI, No. (% total courses) | 9 (10.2) | 3 (4.1) | .2 | 1 (1.1) | ND |
| Breakthrough IPA, No. (% total courses) | 6 (6.8) | 1 (1.3) | .1 | 0 | ND |
| bIFI, non-IPA, No. (% total courses) | 3 (3.4) | 2 (2.8) | 1 | 1 (1.1) | ND |
Abbreviations: AML, acute myeloid leukemia; bIFI, breakthrough invasive fungal infection; IPA, invasive pulmonary aspergillosis; ISA, isavuconazole; ND, not determined; POS, posaconazole; R/R, relapsed/refractory; VOR, voriconazole.
aISA vs VOR.
bPossible with positive polymerase chain reaction.